NSCLC臨床試験分析：10社以上の企業と治療法による強力なパイプラインに関する重要な洞察 | DelveInsight

DelveInsight’s “Non-Small-Cell Lung Cancer Pipeline Insight 2025” report delivers in-depth analysis of the NSCLC pipeline, highlighting more than 10 companies and 10+ emerging therapies. It encompasses detailed profiles of NSCLC pipeline drugs across clinical and preclinical stages, along with assessments based on product type, development stage, administration route, and molecule type. The report also covers inactive pipeline products in this therapeutic area.

Dive into the full spectrum of insights from DelveInsight to stay at the forefront of the NSCLC treatment landscape. Click here for more @ NSCLC Pipeline Outlook-https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr 

Key Highlights from the NSCLC Pipeline Report

• In June 2025, Revolution Medicines Inc. unveiled a global, randomized, open-label Phase 3 trial to assess the safety and effectiveness of a novel RAS(ON) inhibitor against docetaxel. The study aims to compare daraxonrasib's impact on progression-free survival (PFS) and overall survival (OS) with docetaxel in previously treated NSCLC patients, randomizing participants 1:1.
• In June 2025, Amgen initiated a study to evaluate the safety and efficacy of two dose levels of AMG 193, with monotherapy effectiveness reviewed by a Blinded Independent Central Review (BICR).
• In June 2025, Allist Pharmaceuticals Inc. launched a Phase 3 trial to compare the efficacy and safety of adjuvant firmonertinib versus placebo in Stage IB-IIIB NSCLC patients with uncommon EGFR mutations (including exon 20 insertions, PACC, and classical-like mutations) following complete surgical resection, with or without prior adjuvant chemotherapy.
• In June 2025, AstraZeneca disclosed a Phase III trial to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy against standard-of-care platinum-based chemotherapy as first-line treatment for EGFR and ALK wild-type advanced or metastatic NSCLC.

DelveInsight’s NSCLC pipeline report reveals a dynamic field with over 10 active players advancing more than 10 therapies for NSCLC management.

Leading NSCLC developers include major pharmaceutical firms like GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi. Innovative biotech companies such as IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc.,OBI Pharma , Yuhan Corporation ,Chugai Pharmaceutical , and others are also key contributors.

Yuhan Corporation is advancing Lazertinib (YH25448), a third-generation EGFR tyrosine kinase inhibitor selective for activating EGFR mutations and T790M, currently in Phase 1, 2, and 3 trials. The Phase 1/2 trial is identified as NCT03046992, while the Phase 3 LASER301 trial (NCT04248829) met its primary endpoint compared to gefitinib in EGFR-mutated NSCLC. Lazertinib is approved in Korea and partnered globally. Additionally, Yuhan Corporation, in collaboration with Janssen, is developing the combination of Amivantamab and Lazertinib. Amivantamab is an EGFR/MET bispecific antibody with immune effector function, and Lazertinib is an EGFR TKI; this combination is in Phase 3 under the MARIPOSA trial (NCT04487080), which demonstrated statistically significant overall survival and progression-free survival benefits versus standard EGFR TKIs. The combination is approved or under regulatory review in multiple regions, including Asia.

Chugai Pharmaceutical is involved with Alectinib, an ALK tyrosine kinase inhibitor, in Phase 3 post-approval lifecycle studies. Multiple global trials, such as those in the ALEX lineage, support its use, and recent Japanese label updates include adjuvant and early-line settings based on accumulated global data. Japanese industry-sponsored platform trials, involving various pharmaceutical companies, are evaluating multiple investigational agents and combinations in Phase 1b and 2, with a mixed mechanism of action including immunotherapy combinations and targeted agents. The trial ID is jRCT2031250529, and it focuses on novel drug combinations in advanced NSCLC, with Japanese companies as formal sponsors or co-sponsors.

OBI Pharma does not have any directly sponsored NSCLC trials, focusing instead on ADC and cancer vaccine platforms targeting Globo-H, TROP2, and Nectin-4, with an emphasis on earlier-stage and non-lung indications. Other Taiwanese biotech sponsors primarily participate as trial sites rather than primary sponsors, with no confirmed Phase 1–3 NSCLC trials led by Taiwanese companies in public registries.

Notable NSCLC pipeline therapies include Brigatinib, Tyrosine kinase inhibitors, sintilimab in combination with anlotinib, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab, and more.

Keep up with the latest breakthroughs in NSCLC therapies. Download for updates and join the evolution in oncology care @ NSCLC Clinical Trials Assessment.-https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

NSCLC Emerging Drugs Profile

AMG 510: Amgen Developed by Amgen, AMG 510 completed Phase 1 trials in late 2020. Targeting the G12C KRAS mutation—present in about 14% of NSCLC adenocarcinoma cases and 5% of colorectal cancers—AMG 510 is the pioneering drug for this mutation, generating significant anticipation. It has received Fast Track designation from the FDA for metastatic NSCLC with the G12C KRAS mutation and is now in the preregistration phase for NSCLC treatment.

CMP 001: Cytos Biotechnology CMP 001 is a short DNA oligonucleotide mimicking bacterial DNA, encapsulated in noninfectious virus-like particles (VLPs). Designed for direct tumor administration, it triggers the immune system to recognize VLPs as foreign, activating antigen-presenting cells to release the DNA. CMP 001 is currently in Phase 1 trials for NSCLC.

Insights from the NSCLC Pipeline Report

The report offers comprehensive details on companies developing NSCLC therapies, including the total number of therapies per company. It segments therapeutic candidates into early, mid, and late development stages for NSCLC. It also examines targeted therapeutics, including active and inactive (dormant or discontinued) projects. Drugs are analyzed by development stage, administration route, target receptor, monotherapy or combination approach, mechanism of action, and molecular type. Additionally, it provides an in-depth look at collaborations (company-to-company and company-academia), licensing deals, and funding for advancing the NSCLC market. Discover more about NSCLC drug opportunities in our innovative research and development initiatives @ NSCLC Unmet Needs- https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

NSCLC Companies

Prominent players include GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi. Innovative biotech companies such as IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc.,OBI Pharma , Yuhan Corporation ,Chugai Pharmaceutical , and others are also actively engaged.

The Non-Small-Cell Lung Cancer (NSCLC) pipeline report evaluates therapies by route of administration, categorizing products as:

• Subcutaneous
• Intravenous
• Oral
• Parenteral
• Intramuscular

By molecule type, NSCLC products are classified as:

• Small molecules
• Peptides
• Polymers
• Gene therapies
• Monoclonal antibodies

By product type, explore the newest developments in NSCLC treatment on our site. Stay updated on our contributions to neurology's future @ NSCLC Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Scope of the NSCLC Pipeline Report

• Coverage: Global
• NSCLC Companies: GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi. Innovative biotech companies such as IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc.,OBI Pharma , Yuhan Corporation ,Chugai Pharmaceutical , and others.
• NSCLC Pipeline Therapies: Brigatinib, Tyrosine kinase inhibitors, sintilimab with anlotinib, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab, and more.
• NSCLC Therapeutic Assessment by Product Type: Monotherapy, Combination, Monotherapy/Combination.
• NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III.

For a complete summary of our recent research and upcoming strategies, explore the full NSCLC Pipeline details on our website @ NSCLC Emerging Drugs and Companies-https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Table of Contents

• Introduction
• Executive Summary
• Non-Small-Cell Lung cancer (NSCLC): Overview
• Pipeline Therapeutics
• Therapeutic Assessment
• Non-Small-Cell Lung cancer (NSCLC) – DelveInsight’s Analytical Perspective
• In-depth Commercial Assessment
• Late Stage Products (Pre Registration)
• AMG 510: Amgen
• Drug profiles in the detailed report…..
• Mid Stage Products (Phase II)
• Drug Name: Company Name
• Drug profiles in the detailed report…..
• Early Stage Products (Phase I)
• CMP 001: Cytos Biotechnology
• Inactive Products
• Non-Small-Cell Lung cancer (NSCLC) Key Companies
• Non-Small-Cell Lung cancer (NSCLC) Key Products
• Non-Small-Cell Lung cancer (NSCLC)- Unmet Needs
• Non-Small-Cell Lung cancer (NSCLC)- Market Drivers and Barriers
• Non-Small-Cell Lung cancer (NSCLC)- Future Perspectives and Conclusion
• Non-Small-Cell Lung Cancer (NSCLC) Analyst Views
• Non-Small-Cell Lung cancer (NSCLC) Key Companies
• Appendix

About Us

DelveInsight is a premier healthcare market research and consulting firm, delivering high-quality intelligence and analysis to guide strategic decisions. Our expert team, with deep expertise in life sciences and healthcare, provides tailored research solutions worldwide. Reach out for accurate, timely insights to lead in your industry. Connect with us to stay ahead of the curve.

Related Reports

Non-Small Cell Lung Cancer (NSCLC) Market Insight, Epidemiology and Market Forecast -2034

DelveInsight's “Non-small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of top oncogenic drivers/biomarkers in NSCLC (such as EGFR, c-MET, ROS1, KRAS, ALK, HER2, BRAF, RET fusion, NRG1 Fusion, NTRK1/2/3 gene fusion, PD-L1, etc.), historical and forecasted epidemiology as well as the NSCLC market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The NSCLC therapeutics market is driven by advancements in targeted therapies, immunotherapy, and personalized medicine, improving patient outcomes globally.The leading NSCLC Companies developing therapies include - AstraZeneca, Boehringer Ingelheim, Pfizer, Takeda, Johnson & Johnson Innovative Medicine, Eli Lilly and Company, Merck, Bristol-Myers Squibb, Roche, Shanghai Henlius Biotech, AbbVie, Daiichi Sankyo, Nuvation Bio, PDC*line Pharma, Moderna Therapeutics, Pfizer, GSK, Gilead Sciences, BieGene, Nuvalent, and others.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Kanishk Kumar

Email: kkumar@delveinsight.com 

Phone: 09650213330

Address: 304 S. Jones Blvd #2432

City: Las Vegas

State: NV

Country: United States

Website: https://www.delveinsight.com/